Life sciences and healthcare lawyers

Our UK and Boston Life Sciences team acts as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.

Advised on the formation of GADx by the acquisition of two companies, Mologic and Global Access Diagnostics, by a consortium of social impact investors called Global Access Health. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. We also advise on licensing and facilities agreements, manufacturing agreement and customer contracts.

We acted for Lupin in relation to its acquisition of the minority shareholding in a pharmaceutical company in Australia.

A Cambridge-based clinical stage biotech company that leads in the inhibition of p300/CBP to treat multiple specific cancer types. CellCentric raised $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477.  We advised CellCentric with respect to this equity funding round from Morningside Venture Investments Limited and BridgeEdge, the impact venture capital fund of the American Cancer Society

Our UK and Boston Life Sciences team acts as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.

NRG Therapeutics - We advised Parkinson's UK on its investment which formed part of the $18.3m (£16m) Series A funding round of NRG Therapeutics to help progress the development of mitochondrial therapeutics to treat neurodegenerative ailments such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Led by Omega Funds, the financing round also saw participation from new investor Brandon Capital. NRG Therapeutics is Cambridge based and leverages breakthrough science in the mitochondrial biology field to create disease-altering therapies to slow down or stop the progression of diseases such as Parkinson’s and ALS. This transaction combines the expertise of Wither Tech for venture capital and charities to help guide the innovative virtual biotech arm of Parkinson's UK in making this investment.  Wither tech team also advises Parkinson's UK on intellectual property matters such as IP protection and funding agreements.

Roslin Tech is an Edinburgh-based food and agritech company that spun out of the Roslin Institute and has developed pluripotent animal stem cells with the capacity to self-renew indefinitely and differentiate into end-tissues for meat.  The Withers tech team has advised food and agritech company Roslin Technologies Limited, on their £11 million Series A funding round. The financing was led by Novo Holdings, joined by Kairos Capital Group, Future Planet Capital, Esco Lifesciences, Alchimia, Nutreco and private investors.  The Withers tech team also advises RoslinTech on commercial matters such as complex licensing and collaboration agreements and IP protection

Acted for Medovate Limited, in respect of the set up and venture capital funding of this company established to enable and promote the commercialisation of intellectual property and medical products from NHS Trust in East Anglia.

Acting as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.

Advised on the formation of GADx by the acquisition of two companies, Mologic and Global Access Diagnostics, by a consortium of social impact investors called Global Access Health. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. We also advise on licensing and facilities agreements, manufacturing agreement and customer contracts.

Advised an Italian company in its acquisition of the U.S. subsidiary of a U.K. company in the pharmaceutical industry.

We acted for the CEO of an international and award winning pharmaceutical company in relation to her acrimonious exit. As a co-founder of the business and a minority shareholder, we negotiated the terms of her multi-million pound settlement, working closing with one of the top four accountants on valuation issues.

Advised on the formation of GADx by the acquisition of two companies, Mologic and Global Access Diagnostics, by a consortium of social impact investors called Global Access Health. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. We also advise on licensing and facilities agreements, manufacturing agreement and customer contracts.

Advised an Italian company in its acquisition of the U.S. subsidiary of a U.K. company in the pharmaceutical industry.

Advised in the acquisition of and merger into a biotech/healthcare company based in North Carolina.

Advised, as lead investor counsel, in a reorganization, US$1 million bridge loan, and US$7 million strategic investment by a leading pharmaceutical company in a biotech/medical company based in California.

We were instructed to form a master LLC (limited liability company) to buy, build, own and occupy a state-of-the-art medical office building in the US. We also negotiated the permanent financing and construction, and arranged all the leases for our client.